International Journal of Technology Assessment in Health Care · 2001 · 70 citations · 5 references
PharmacyBiostatisticsPharmacoeconomicsBayesian BiostatisticsCost-effectiveness AnalysisUncertainty QuantificationBayesian InferenceBayesian ModelingBayesian StatisticsCost-effectiveness ModelingHealthcare Cost AnalysisModel-based Economic EvaluationBayesian Economic ModelingBayesian EstimationCost-effectivenessIncorporating Auxiliary DataIncremental Cost EstimationPlasminogen ActivatorsProbabilistic Cost ModelingStatistical Uncertainty Estimation
A desirable element of cost-effectiveness analysis (CEA) modeling is a systematic way to relate uncertainty about input parameters to uncertainty in the computational results of the CEA model. Use of Bayesian statistical estimation and Monte Carlo simulation provides a natural way to compute a posterior probability distribution for each CEA result. We demonstrate this approach by reanalyzing a previously published CEA evaluating the incremental cost-effectiveness of tissue plasminogen activator compared to streptokinase for thrombolysis in acute myocardial infarction patients using data from the GUSTO trial and other auxiliary data sources. We illustrate Bayesian estimation for proportions, mean costs, and mean quality-of-life weights. The computations are performed using the Bayesian analysis software WinBUGS, distributed by the MRC Biostatistics Unit, Cambridge, England.
5
Daniel B. Mark, Mark A. Hlatky, Robert M. Califf et al. · New England Journal of Medicine · 1995 · 524 citations · Full text
Placing Trials in Context Using Bayesian Analysis
James M. Brophy · JAMA · 1995 · 154 citations